Recent News

• 08.06.2026 - CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
• 07.30.2026 - BCAN Think Tank 2026 – Creto EAP Poster and Podium
• 07.28.2026 - THE LANCET ONCOLOGY 2026 PUBLICATION
• 07.27.2026 - CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
• 06.29.2026 - CUA 2026 – BOND-003 Cohort C Podium
• 05.28.2026 - CG Oncology to Present at Upcoming Investor Conferences in June
• 05.19.2026 - SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
• 05.15.2026 - AUA 2026 – CORE 008 Cohort CX Presentation
• 05.15.2026 - CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
• 05.11.2026 - CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC

Recent Filings

• 08.06.2026 - 144 Report of proposed sale of securities
• 08.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.06.2026 - 8-K Current report
• 08.06.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 08.06.2026 - EX-99.1 EX-99.1
• 08.05.2026 - 144 Report of proposed sale of securities
• 07.29.2026 - 144 Report of proposed sale of securities
• 07.28.2026 - 144 Report of proposed sale of securities
• 07.27.2026 - 144 Report of proposed sale of securities
• 07.27.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors